Probiotics for Prevention of Ventilator-Associated Pneumonia (VAP)
- Conditions
- Drug Safety
- Interventions
- Other: ProbioticsOther: control
- Registration Number
- NCT01301131
- Lead Sponsor
- Mahidol University
- Brief Summary
Hospitalized patients with ventilator are randomized to receive fermented dairy product containing L. casei shirota or nothing. The main outcome is development of ventilator-associated pneumonia (VAP)
- Detailed Description
Fermented dairy product containing L. casei shirota has bee shown to inhibit multi-drug-resistant bacteria. This study is conducted to determine if Fermented dairy product containing L. casei shirota can prevent ventilator-associated pneumonia.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 150
Patient age ≥ 18-year who received ventilator and agreed to participate by signing informed consent form
Immunocompromised host (e.g. HIV infection, On immunosupressive agents, ANC ≤ 500 cell/ml), Pregnancy, History of congenital heart disease, rheumatic fever, previously infective endocarditis, prosthetic valve, Contraindication for enteral feeding, History of milk or milk-product allergy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Probiotic Probiotics 80 ml of fermented dairy product containing L. casei shirota via nasogastric tube once daily and 80 ml of fermented dairy product containing L. casei shirota oral rinse once daily control control -
- Primary Outcome Measures
Name Time Method Number of subjects with pneumonia up to 28 days patient with pneumonia
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Siriraj Hospital
🇹🇭Bangkok, Thailand